Keith Cooper
0000-0002-0318-7670
University of Southampton
68 papers found
Refreshing results…
Bimekizumab for treating active psoriatic arthritis
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer
Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma
Cost-effectiveness of a dietary and physical activity intervention in adolescents: a prototype modelling study based on the Engaging Adolescents in Changing Behaviour (EACH-B) programme
Nintedanib for treating idiopathic pulmonary fibrosis in people with a forced vital capacity above 80% predicted (part-review of technology appraisal guidance 379)
Avalglucosidase alfa for treating Pompe disease
Atezolizumab for untreated PD-L1 positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF review TA492): a single technology appraisal
Semaglutide for managing overweight and obesity
Faricimab for treating diabetic macular oedema
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours:
Apalutamide for treating prostate cancer - A Single Technology Appraisal
Dupilumab for treating severe asthma: Report for NICE Technology Appraisal (TA751)
The testing of people with any risk factor for hepatitis C in community pharmacies is cost‐effective
Pembrolizumab in combination with axitinib for untreated advanced renal cell carcinoma
Budesonide for treating eosinophilic oesophagitis:
Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Reslizumab for Treating Asthma with Elevated Blood Eosinophils Inadequately Controlled by Inhaled Corticosteroids: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease. A Single Technology Appraisal
Fulvestrant for untreated hormone-receptor positive locally advanced metastatic breast cancer
Missing publications? Search for publications with a matching author name.